Manage episode 231974580 series 2394758
An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.
Check out more of our content here:
1405 episodes available. A new episode about every day averaging 27 mins duration .